TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05789524

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“Study terminated due to business and strategic decision”

The sponsor’s own words in the registry.

Life of this trial

2023202420252026Registered2023-03-16Started2023-07-06Primary completion2024-11-14Stopped2025-02-28

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
ApcinteX Ltd
Sponsor type
Industry
Conditions
Hemophilia a; Hemophilia B
Interventions
SerpinPC
Participants
60
Sites
59
Countries
Armenia, Australia, Belgium, Canada, France, Germany, India, Italy, Poland, South Africa, Spain, Taiwan and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.